Skip to main content
Vertex's cystic fibrosis combo drug approved by FDA

Vertex Pharmaceuticals' Symdeko, or tezacaftor/ivacaftor and ivacaftor, was approved by the FDA as a treatment for patients at least 12 years of age with cystic fibrosis who have two copies of the F508del mutation in the CFTR gene or at least one mutation that responds to tezacaftor/ivacaftor.

Full Story: